

=====

TRADEMARK AND INTELLECTUAL PROPERTY
BIOPHARMA INDUSTRIES LIMITED

=====

CONTROLLER GENERAL OF PATENTS, DESIGNS AND TRADEMARKS
TRADEMARK REGISTRY OF INDIA

=====

SECTION 1: COMPANY TRADEMARK REGISTRATIONS

=====

1.1 CORPORATE TRADEMARK

Trademark: BIOPHARMA INDUSTRIES
Application Number: 2456789
Registration Number: 2456789
Class: 5 (Pharmaceutical preparations and substances)
Status: REGISTERED

Proprietor: BioPharma Industries Limited
Plot No. 234-235, MIDC Industrial Area
Thane - 400701, Maharashtra

Filing Date: January 20, 2012
Registration Date: August 15, 2013
Valid Until: January 19, 2032 (Renewed)
Renewal Due: January 19, 2032

Description: Word mark "BIOPHARMA INDUSTRIES" in standard characters

Goods Covered: Pharmaceutical and medicinal preparations, tablets, capsules, syrups, ointments, medical and veterinary preparations, substances, all included in Class 5

Attorney: M/s. IP Rights LLP, Mumbai

Ref: IPR/TM/BIO/2012/001

1.2 CORPORATE LOGO

Trademark: [BioPharma Logo - Molecule Design]

Application Number: 2567890

Registration Number: 2567890

Class: 5

Status: REGISTERED

Filing Date: March 15, 2012

Registration Date: November 20, 2013

Valid Until: March 14, 2032 (Renewed)

Description: Device mark comprising a stylized molecule symbol in blue and green colors with company name

SECTION 2: BRAND NAME REGISTRATIONS

The Company has registered the following brand names for its pharmaceutical products:

S.No	Brand Name	App. No.	Reg. No.	Class	Status	Valid Until
1.	AMOXYBIO (Amoxicillin products)	3456789	3456789	5	Registered	Mar 2031
2.	METBIO (Metformin products)	3567890	3567890	5	Registered	Apr 2031
3.	AMLOBIO (Amlodipine products)	3678901	3678901	5	Registered	May 2031
4.	ATORBIO (Atorvastatin products)	3789012	3789012	5	Registered	Jun 2031
5.	AZIBIO (Azithromycin products)	3890123	3890123	5	Registered	Jul 2031
6.	PANTOBIO (Pantoprazole products)	3901234	3901234	5	Registered	Aug 2031
7.	CEFIBIO (Cefixime products)	4012345	4012345	5	Registered	Sep 2031
8.	ROSSBIO (Rosuvastatin products)	4123456	4123456	5	Registered	Oct 2031
9.	TELBIO (Telmisartan products)	4234567	4234567	5	Registered	Nov 2031

10. LOSARBIO 4345678 4345678 5 Registered Dec 2031
(Losartan products)

11. OMEBIO 4456789 4456789 5 Registered Jan 2032
(Omeprazole products)

12. MONTBIO 4567890 4567890 5 Registered Feb 2032
(Montelukast products)

ALL TRADEMARKS ARE:

- Registered in Class 5 (Pharmaceuticals)
 - Renewed timely with no lapses
 - No opposition proceedings pending
 - No infringement claims
-

SECTION 3: FREEDOM TO OPERATE OPINIONS

BioPharma Industries manufactures generic pharmaceutical formulations. For each product, the Company has obtained legal opinions confirming freedom to operate.

3.1 SAMPLE FREEDOM TO OPERATE OPINION

LEGAL OPINION: FREEDOM TO OPERATE

Product: Atorvastatin Calcium Tablets 10mg/20mg/40mg/80mg

Prepared By: M/s. IP Rights LLP, Patent and Trademark Attorneys

Date: March 15, 2017

Reference: IPR/FTO/BIO/2017/ATOR/001

EXECUTIVE SUMMARY:

Based on our review of the patent landscape, we opine that BioPharma Industries Limited is free to manufacture, market, and sell Atorvastatin Calcium Tablets in the Indian market and for export to non-regulated markets.

ANALYSIS:

1. ACTIVE PHARMACEUTICAL INGREDIENT (API):

Original Innovator: Pfizer Inc. (Brand: Lipitor)

Original Patent: US Patent No. 4,681,893 (Compound patent)

Indian Patent Status: No compound patent granted in India (pre-2005)

Expiry in USA: November 2011

Status: API is off-patent globally

2. FORMULATION PATENTS:

A search of the Indian Patent Office database and global patent databases was conducted for formulation patents covering atorvastatin tablets.

Patents Identified: 12 formulation patents globally

Patents in India: 3 patents granted

Analysis of Indian Patents:

a) IN 234567 - Controlled release formulation of atorvastatin

Patentee: XYZ Pharma

Expiry: 2025

Relevance: NOT RELEVANT - BioPharma's product is immediate release, not controlled release. Different formulation approach.

b) IN 345678 - Combination of atorvastatin with ezetimibe

Patentee: ABC Labs

Expiry: 2026

Relevance: NOT RELEVANT - BioPharma's product is single entity atorvastatin, not a combination product.

c) IN 456789 - Stabilized atorvastatin formulation using specific excipients

Patentee: PQR Healthcare

Expiry: 2024

Relevance: POTENTIALLY RELEVANT - Patent claims specific combination of excipients for stability.

Detailed Analysis: BioPharma's formulation uses different excipients and different ratios. Patent claims are limited to specific excipient combination. BioPharma's formulation does not infringe the claims.

CONCLUSION: NO INFRINGEMENT

3. MANUFACTURING PROCESS PATENTS:

No process patents identified that would restrict manufacture of atorvastatin tablets using conventional wet granulation process.

4. CONCLUSION:

Based on the above analysis, we opine that:

a) The API atorvastatin calcium is off-patent and freely available.

b) BioPharma Industries' formulation of Atorvastatin Calcium Tablets does not infringe any valid and subsisting patent in India.

c) BioPharma Industries is free to manufacture, market, and sell Atorvastatin Calcium Tablets in India and export markets.

d) For regulated markets (US, EU), separate patent analysis considering local patent laws should be conducted.

LIMITATIONS:

- This opinion is based on patent search conducted as of the date hereof.
- New patents may be granted after this date.
- This opinion covers India only.
- Trademark and regulatory aspects are not covered.

Sd/-

Mr. Rahul Mehta
Partner, M/s. IP Rights LLP
Registered Patent Agent

3.2 FREEDOM TO OPERATE STATUS FOR ALL PRODUCTS

Product	FTO Opinion Date	Status	Expiry Risk
Amoxicillin Capsules	Feb 2014	Clear	None
Metformin Tablets	Mar 2014	Clear	None
Amlodipine Tablets	Apr 2014	Clear	None

Atorvastatin Tablets	Mar 2017	Clear	None
Azithromycin Tablets	May 2018	Clear	None
Omeprazole Capsules	Jun 2016	Clear	None
Pantoprazole Tablets	Jul 2016	Clear	None
Cefixime Tablets	Feb 2017	Clear	None
Rosuvastatin Tablets	Aug 2019	Clear	None
Telmisartan Tablets	Sep 2020	Clear	None
Losartan Tablets	Oct 2019	Clear	None
Montelukast Tablets	Nov 2021	Clear	None
Dapagliflozin Tablets	Dec 2024	Clear*	*Patent watch

* Dapagliflozin: Compound patent expired in India in 2024. Product launch planned for FY 2025-26 after confirmation of patent expiry.

SECTION 4: PATENTS HELD BY THE COMPANY

BioPharma Industries is primarily a generic pharmaceutical company and does not hold any product patents. The Company holds only process/formulation improvement patents:

STATUS: NIL

The Company has not filed any patent applications to date.

SECTION 5: TRADE SECRET AND KNOW-HOW

The Company maintains the following as trade secrets and confidential know-how:

1. Proprietary manufacturing processes for certain products
2. Bioequivalence study protocols and data
3. Stability improvement techniques
4. Formulation optimization methods
5. API vendor qualification data

Protection Measures:

- Confidentiality agreements with all employees
 - Restricted access to R&D and manufacturing areas
 - Document classification system
 - IT security measures
-

SECTION 6: DOMAIN NAME REGISTRATIONS

Domain Name	Registrar	Expiry Date	Status
biopharma.com	GoDaddy	Dec 2026	Active
biopharmaindia.com	GoDaddy	Dec 2026	Active
biopharma.in	NIXI	Dec 2026	Active
biopharma.co.in	NIXI	Dec 2026	Active

SECTION 7: COPYRIGHT REGISTRATIONS

The Company has registered copyright for:

1. Product literature and marketing materials
2. Training manuals and SOPs (compilation)
3. Software developed in-house for production tracking

Registration Numbers:

- L-78901/2018 (Product catalog)
 - L-89012/2019 (Employee handbook)
 - SW-9012/2020 (Production tracking software)
- =====

SECTION 8: IP ASSIGNMENT AGREEMENT

=====

All employees involved in R&D activities have executed IP Assignment Agreements assigning all intellectual property created during employment to the Company.

Key Terms:

- All inventions made during employment belong to Company
- Employee to disclose all inventions promptly
- Employee to assist in patent filing
- Assignment includes all future patents, copyrights, trade secrets
- Survives termination of employment

Employees covered: 52 (All R&D and technical staff)

Compliance: 100%

=====

SECTION 9: IP AUDIT AND VALUATION

Last IP Audit: June 2024
Conducted By: M/s. IP Rights LLP

Findings:

- All trademarks current and renewed
- No infringement risks identified
- FTO opinions current for all products
- Trade secret protection adequate

Valuation of Intangibles:

- Trademarks: Rs. 5.2 Crores
- Know-how: Rs. 8.5 Crores
- Total: Rs. 13.7 Crores

(Valuation as per Income Approach by independent valuer)

SECTION 10: IP-RELATED LITIGATION

CURRENT STATUS: NIL

No IP-related litigation pending either against the Company or initiated by the Company.

No cease and desist notices received in last 5 years.
No opposition proceedings in trademark matters.

=====

SECTION 11: CONTACT FOR IP MATTERS

=====

Internal Contact:

Name: Ms. Priya Desai
Designation: Manager - Regulatory and IP Affairs
Email: ip@biopharma.com
Phone: +91-22-2568-XXXX

External Counsel:

Firm: M/s. IP Rights LLP
Contact: Mr. Rahul Mehta, Partner
Address: 12th Floor, Maker Chambers IV, Nariman Point, Mumbai
Email: rahul@iprights.co.in
Phone: +91-22-4567-XXXX

=====

END OF TRADEMARK AND IP DOCUMENTATION

=====